ARTICLE | Company News

FDA panel affirms safety of Pfizer's Celebrex

April 25, 2018 8:48 PM UTC

FDA's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 15-5 that the Phase IV CV outcomes PRECISION trial showed that Celebrex celecoxib from Pfizer Inc. (NYSE:PFE) had comparable cardiovascular safety to non-selective NSAIDS naproxen and ibuprofen.

Celebrex is an NSAID that selectively inhibits cyclooxygenase-2 (COX-2)...

BCIQ Company Profiles

Pfizer Inc.

BCIQ Target Profiles

Cyclooxygenase-2 (COX-2)